Systemic administration of nac as an adjunct in the treatment of bioterror exposures such as smallpox and use in combination with dhea for the treatment of smallpox

Abstract

The invention is for the combination and related methods of N-acetyl-cysteine oral, inhaled, or intravenous, or glutathione inhaled or intravenous, generally in combination with antibiotic and/or antiviral therapy to ameliorate the toxic effects of infection with materials used in Bioterror incidents such as Bacillus anthracis and smallpox virus, and alternatively, upon exposure to radiation, during testing, and vaccination, as treatment prior to treatment with antibiotic or antiviral therapy to ameliorate the toxic effects of infection and exposure with these organisms.

1 . A combination for ameliorating the effects of exposure of a person to smallpox as a viral bioterror weapon, comprising:
 in a pharmaceutically acceptable carrier, a therapeutic dose of NAC and a therapeutic dose of at least one antiviral agent to said smallpox as the viral bioterror weapon.   
     
     
         2 . The combination according to  claim 1 , further comprising:
 a therapeutic dose of Selenium.   
     
     
         3 . The claim according to  claim 2 , further comprising:
 a therapeutic dose of dehydroepiandrosterone.